Myasthenia Gravis clinical trials
38 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
- A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
- Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
- Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
- ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
- Myasthenia Gravis Foundation of America Global MG Patient Registry
- A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Vitaccess Real MG Registry
- The EXPLORE MG Registry for Myasthenia Gravis
- Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
- FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
- The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
- PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry
- Serum Auto-Antibodies in Neurological Diseases
- Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Myasthenia Gravis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.